Structure Therapeutics Expected to Post Q1 Loss of 35 Cents, Following Consistent Earnings Misses
GPCR has more than doubled off its 52-week low of $15.8.
Summary
Structure Therapeutics is expected to report a loss of 35 cents per share for the first quarter ending March 31, 2026, with no change in quarterly revenue anticipated. This earnings preview is notable given the company's consistent history of significantly missing analyst estimates in the past eight consecutive quarters. While analysts maintain a "buy" rating and a high price target, the pattern of underperformance against expectations introduces a material risk for the stock around the upcoming earnings release. Traders will be closely monitoring the actual results on May 6th to assess if this trend of missing estimates persists.
At the time of this announcement, GPCR was trading at $43.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $15.80 to $94.90. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.